AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04285658 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Nephrolithotomy
Description: A minimally invasive surgery in which a \~1cm flank incision is made, and a scope is passed through a tubular sheath into the kidney to fragment and remove the stone. There is typically a 1- to 2-day hospital stay. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
Study NCT04285658 — intervention group
Intervention type: PROCEDURE
Intervention: Shock Wave Lithotripsy
Description: A non-invasive outpatient procedure that targets stones in the kidney or ureter with x-ray or ultrasound and uses shockwaves generated outside the body to fragment them; the fragments pass down the ureter and the patient expels them in the urine. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
Study NCT03091686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA SB Intervention Slideshow
Description: In the experimental condition, participants will receive sedentary behaviour and diabetes information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. For the experimental group, the intervention material will target risk perceptions (RP) related to sitting by presenting evidence supported by research on sedentary behaviour and diabetes risk; outcome expectancies (OE) by presenting research on the effectiveness of breaking up sedentary time for improving blood sugar and insulin levels; and self-efficacy (SE) by providing strategies on how to reduce and break up sitting time.
Study NCT03091686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HAPA MVPA Attention-Control Slideshow
Description: In the attention-control, participants will receive information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. The attention-control slide show will take the same approach as the Experimental group slideshow but the slides will be geared towards meeting moderate-vigorous physical activity guidelines.
Study NCT02104492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a 12-week Respiratory Muscles Training Program (RMTP)
Description: Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
Study NCT02104492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
Study NCT00845884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
Description: * Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~* Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days.
Study NCT03253484 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NAFL-treatment
Description: non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
Study NCT02914925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmeoSpring/CIT
Description: Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
Study NCT02768454 — intervention group
Intervention type: DRUG
Intervention: medical review of controlled broad-spectrum antibiotics
Description: medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
Study NCT00603577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
Study NCT00603577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaliproden
Description: 1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
Study NCT04603976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Study NCT03179644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of oesophageal pressure and pleural pressure
Description: Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
Study NCT04234113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp alfa
Description: A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15
Study NCT04234113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanized IgG4 monoclonal antibody with high specificity of binding to the PD-1 receptor
Study NCT04245085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit.
Study NCT01382433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetoencephalograph (MEG)
Description: Brain imaging device that records the magnetic fields in the brain.
Study NCT00730730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete SE Iliac Stent
Description: Iliac stenting
Study NCT04245085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
Study NCT04245085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
Study NCT01382433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cambridge Neuropsychological Test Automated Battery (CANTAB).
Description: the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
Study NCT04245085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
Study NCT01382433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)
Description: The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
Study NCT03175237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Study NCT04310410 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combined radiotherapy and MR-HIFU
Description: Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.
Study NCT04388891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally supervised therapy with the ReHapticKnob
Description: The therapy with the ReHapticKnob is performed in the clinic in addition to the conventional therapy. During the supervised and semi-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes. During the minimally supervised phase (third and fourth week), the duration of the ReHapticKnob therapy is not specified, since the patient can decide by him/herself when to use the device, e.g. during freetime or during the weekend.
Study NCT01183000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the peritoneum at cs
Description: Injection of 5 mg Marcaine (anesthetic solution) to the leg
Study NCT02890823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study NCT02890823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study NCT00405977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
Study NCT00405977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
Study NCT04245085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
Study NCT03083210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
Study NCT03982433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation and Cognitive Behavioral Management for Alcohol and Pain
Description: Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
Study NCT00673361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent decrescendo biochemotherapy regimen
Description: * Temozolomide: 200mg/m\^2, daily, PO, days 1-4~* Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4~* Cisplatin: 20mg/m\^2, daily IV, days 1-4~* IL (interleukin)-2: - 18 milli-International unit (MIU)/m\^2, IVCI (intravenous continual infusion), day 1~* 9 MIU/m\^2, IVCI, day 2~* 4.5 MIU/m\^2, IVCI, days 3 \& 4~* Interferon (IFN) alpha: 5 MIU/m\^2, daily, SC (subcutaneously), days 1-5~* 5-day inpatient regimen, to be repeated every 21 days
Study NCT00730730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete SE Iliac Stent
Description: Self-expanding stent
Study NCT00673361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Temozolomide plus Sorafenib
Description: Temozolomide: 75mg/m\^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
Study NCT01982383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse Laser Treatment
Study NCT01982383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Study NCT02801058 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Osteopathic manipulative treatment
Description: Osteopathic manipulative techniques on thoracic diaphragm
Study NCT02801058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Osteopathic manipulative techniques on thoracic diaphragm
Study NCT00650156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg single sc dose
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 MK-0517 (PS80) + 2 mg midazolam
Description: MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 115 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Study NCT02809079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 500mg Bid
Study NCT02809079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone 10mg Qd
Study NCT03453099 — intervention group
Intervention type: OTHER
Intervention: Preoperative Questionnaires
Description: The participants will be asked to complete 5 questionnaires:~1. An abbreviated version of the Caffeine Assessment Tool (CAT)~2. Sleep Questionnaire (SQ)~3. Surgical Fear Questionnaire (SFQ)~4. WHO Alcohol AUDIT Tool~5. WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness
Study NCT03453099 — intervention group
Intervention type: OTHER
Intervention: Postoperative Subjective Pain Scores
Description: After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr postoperatively.
Study NCT00513383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
Study NCT00513383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
Study NCT00513383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
Study NCT00513383 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
Study NCT00513383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
Study NCT00513383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenously on day 1 of a 21-day cycle for 3 cycles
Study NCT00513383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously on day 1 of a 21-day cycle for 3 cycles
Study NCT02992782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Home program of decongestive exercise and daily use of a compression sleeve
Study NCT02992782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Compression Garment
Description: Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
Study NCT02992782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Adjustable Compression Wrap
Description: Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
Study NCT02916810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS stimulation
Description: Participants will receive two rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two rTMS sessions.
Study NCT02916810 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS stimulation
Description: Participants will receive two sham rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two sham rTMS sessions.
Study NCT01737346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine and procarbazine
Description: 1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
Study NCT03514069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Starting dose ruxolitinib 10 mg twice daily
Study NCT03514069 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 60gy for 6 weeks
Study NCT01951534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Reconstruction Decisional Aid (BRDA)
Study NCT01951534 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Study NCT02114229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib will be administered orally at 80 mg/m\^2 per day for enteric coated tablet formulation and 60 mg/m\^2 per day for oral solution formulation.
Study NCT02114229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate will be given at a dose of 5 g/m\^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m\^2/dose.
Study NCT02114229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin will be given intravenously (IV): 75 mg/m\^2 IV infusion.
Study NCT02114229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
Study NCT02114229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be given 1.5 g/m\^2 IV infusion during induction and consolidation.
Study NCT02114229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide will be given 100 mg/m\^2 IV infusion.~In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day.
Study NCT02114229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL\*hr.
Study NCT02114229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Vincristine will be given 1 mg/m\^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
Study NCT02114229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy.
Study NCT02114229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children \< 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
Study NCT03514069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 75mg/m2